MA29672B1 - [3.1.0] hétéroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type I - Google Patents
[3.1.0] hétéroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type IInfo
- Publication number
- MA29672B1 MA29672B1 MA30281A MA30281A MA29672B1 MA 29672 B1 MA29672 B1 MA 29672B1 MA 30281 A MA30281 A MA 30281A MA 30281 A MA30281 A MA 30281A MA 29672 B1 MA29672 B1 MA 29672B1
- Authority
- MA
- Morocco
- Prior art keywords
- heteroarylamides
- bicyclic
- inhibitors
- type
- glycine transport
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
[3.1.0]hétéroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type I La présente invention concerne une série de [3.1.0]hétéroarylamides bicycliques substitués de formule I, dans laquelle les groupes A, Q, X, Y, Z et R1-R5 sont définis de la manière indiquée dans le présent mémoire, qui possèdent une activité comme inhibiteurs du transport de glycine, leurs sels pharmaceutiquement acceptables, des compositions pharmaceutiques les contenant, leur utilisation pour améliorer la cognition et pour le traitement des symptômes positifs et négatifs de la schizophrénie et d'autres psychoses chez des mammifères, y compris les êtres humains.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66947205P | 2005-04-08 | 2005-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29672B1 true MA29672B1 (fr) | 2008-08-01 |
Family
ID=36649611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30281A MA29672B1 (fr) | 2005-04-08 | 2007-10-08 | [3.1.0] hétéroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type I |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20060229455A1 (fr) |
| EP (1) | EP1869019B1 (fr) |
| JP (1) | JP4193949B2 (fr) |
| KR (1) | KR100969402B1 (fr) |
| CN (1) | CN101189228A (fr) |
| AP (1) | AP2007004198A0 (fr) |
| AR (1) | AR056307A1 (fr) |
| AU (1) | AU2006231917B2 (fr) |
| BR (1) | BRPI0608148A2 (fr) |
| CA (1) | CA2603939C (fr) |
| CR (1) | CR9493A (fr) |
| DK (1) | DK1869019T3 (fr) |
| DO (1) | DOP2006000078A (fr) |
| EA (1) | EA014311B1 (fr) |
| ES (1) | ES2520015T3 (fr) |
| GE (1) | GEP20105053B (fr) |
| GT (1) | GT200600136A (fr) |
| HN (1) | HN2006013804A (fr) |
| IL (1) | IL186409A (fr) |
| MA (1) | MA29672B1 (fr) |
| MX (1) | MX2007012463A (fr) |
| NL (1) | NL1031539C2 (fr) |
| NO (1) | NO339422B1 (fr) |
| NZ (1) | NZ563238A (fr) |
| PE (1) | PE20061400A1 (fr) |
| TN (1) | TNSN07380A1 (fr) |
| TW (1) | TW200719890A (fr) |
| UA (1) | UA88518C2 (fr) |
| UY (1) | UY29456A1 (fr) |
| WO (1) | WO2006106425A1 (fr) |
| ZA (1) | ZA200708481B (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008065500A2 (fr) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i |
| WO2009131958A2 (fr) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Composés, compositions et procédés à base de dérivés de triazine |
| US8207205B2 (en) | 2008-04-21 | 2012-06-26 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
| US20090270398A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| WO2010033626A1 (fr) * | 2008-09-19 | 2010-03-25 | Institute For Oneworld Health | Composés, compositions et procédés comprenant des dérivés d'imidazole et de triazole |
| FR2932479A1 (fr) * | 2008-06-13 | 2009-12-18 | Servier Lab | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| ES2439291T3 (es) * | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
| US8642772B2 (en) * | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| WO2010107115A1 (fr) | 2009-03-19 | 2010-09-23 | 大正製薬株式会社 | Inhibiteur de transporteur de glycine |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| US20100267706A1 (en) * | 2009-04-20 | 2010-10-21 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| AR077472A1 (es) * | 2009-07-15 | 2011-08-31 | Taisho Pharmaceutical Co Ltd | Inhibidores de transportador de glicina |
| EP2496228B1 (fr) | 2009-11-06 | 2014-01-15 | SK Biopharmaceuticals Co., Ltd. | Procédés pour traiter un trouble du déficit de l'attention avec hyperactivité |
| KR101783633B1 (ko) | 2009-11-06 | 2017-10-10 | 에스케이바이오팜 주식회사 | 섬유근육통 증후군의 치료 방법 |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| JP2013249257A (ja) * | 2010-09-16 | 2013-12-12 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害物質 |
| JP2013249258A (ja) * | 2010-09-17 | 2013-12-12 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害物質 |
| US8729271B2 (en) | 2010-09-17 | 2014-05-20 | Taisho Pharmaceutical Co., Ltd | Glycine transporter inhibiting substances |
| EP2621902B1 (fr) | 2010-09-28 | 2017-04-12 | Panacea Biotec Ltd | Dérivés de 3-azabicyclo[3.1.0]hexane utiles pour le traitement de troubles du snc |
| WO2014062838A2 (fr) | 2012-10-16 | 2014-04-24 | Tolero Pharmaceuticals, Inc. | Modulateurs de pkm2 et procédés pour les utiliser |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| EP3134406A1 (fr) | 2014-04-24 | 2017-03-01 | Dart Neuroscience (Cayman) Ltd | Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c]pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c]pyridine utilisés comme inhibiteurs de glyt1 |
| EP3215500A1 (fr) | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Composés azétidinyles substitués utilisés comme inhibiteurs de glyt1 |
| MX2020005517A (es) | 2017-12-05 | 2020-11-09 | Sunovion Pharmaceuticals Inc | Formas cristalinas y metodos de produccion de las mismas. |
| US10369134B2 (en) | 2017-12-05 | 2019-08-06 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| WO2020198077A1 (fr) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant |
| TW202108559A (zh) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead抑制劑及其用途 |
| BR112021024108A2 (pt) | 2019-05-31 | 2022-03-22 | Ikena Oncology Inc | Inibidores de tead e usos dos mesmos |
| WO2020247627A1 (fr) | 2019-06-04 | 2020-12-10 | Sunovion Pharmaceuticals Inc. | Formulations à libération modifiée et utilisations associées |
| KR20220125326A (ko) | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
| BR112022026698A2 (pt) | 2020-08-13 | 2023-02-23 | Boehringer Ingelheim Int | Tratamento da deficiência cognitiva associada à esquizofrenia |
| CA3195702A1 (fr) | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Procede de retraitement |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL342818A1 (en) | 1998-03-06 | 2001-07-02 | Janssen Pharmaceutica Nv | Glycin transport inhibitors |
| JP2002212179A (ja) | 2001-01-15 | 2002-07-31 | Wakunaga Pharmaceut Co Ltd | 新規アニリド誘導体又はその塩及びこれを含有する医薬 |
| EP1442018A1 (fr) | 2001-10-31 | 2004-08-04 | Morphochem Aktiengesellschaft Für Kombinatorische Chemie | Nouveaux composes anticancereux |
| FR2838739B1 (fr) | 2002-04-19 | 2004-05-28 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| CN101838271A (zh) * | 2003-10-14 | 2010-09-22 | 辉瑞产品公司 | 作为甘氨酸转运蛋白抑制剂的二环[3.1.0]衍生物 |
| EP1751115A4 (fr) | 2004-05-23 | 2010-10-20 | Gerard M Housey | Modulateurs de theramuteine |
-
2006
- 2006-03-27 BR BRPI0608148-7A patent/BRPI0608148A2/pt not_active IP Right Cessation
- 2006-03-27 GE GEAP200610309A patent/GEP20105053B/en unknown
- 2006-03-27 JP JP2008504868A patent/JP4193949B2/ja not_active Expired - Fee Related
- 2006-03-27 EP EP06727516.4A patent/EP1869019B1/fr not_active Expired - Lifetime
- 2006-03-27 AU AU2006231917A patent/AU2006231917B2/en not_active Ceased
- 2006-03-27 CA CA2603939A patent/CA2603939C/fr not_active Expired - Fee Related
- 2006-03-27 WO PCT/IB2006/000947 patent/WO2006106425A1/fr not_active Ceased
- 2006-03-27 CN CNA2006800198904A patent/CN101189228A/zh active Pending
- 2006-03-27 KR KR1020077025888A patent/KR100969402B1/ko not_active Expired - Fee Related
- 2006-03-27 DK DK06727516.4T patent/DK1869019T3/da active
- 2006-03-27 EA EA200701902A patent/EA014311B1/ru not_active IP Right Cessation
- 2006-03-27 NZ NZ563238A patent/NZ563238A/en not_active IP Right Cessation
- 2006-03-27 ES ES06727516.4T patent/ES2520015T3/es not_active Expired - Lifetime
- 2006-03-27 UA UAA200711021A patent/UA88518C2/ru unknown
- 2006-03-27 AP AP2007004198A patent/AP2007004198A0/xx unknown
- 2006-03-27 MX MX2007012463A patent/MX2007012463A/es active IP Right Grant
- 2006-03-31 DO DO2006000078A patent/DOP2006000078A/es unknown
- 2006-04-05 UY UY29456A patent/UY29456A1/es unknown
- 2006-04-06 PE PE2006000374A patent/PE20061400A1/es not_active Application Discontinuation
- 2006-04-06 US US11/399,071 patent/US20060229455A1/en not_active Abandoned
- 2006-04-06 AR ARP060101362A patent/AR056307A1/es unknown
- 2006-04-06 GT GT200600136A patent/GT200600136A/es unknown
- 2006-04-06 HN HN2006013804A patent/HN2006013804A/es unknown
- 2006-04-07 NL NL1031539A patent/NL1031539C2/nl not_active IP Right Cessation
- 2006-04-07 TW TW095112431A patent/TW200719890A/zh unknown
-
2007
- 2007-10-03 NO NO20074993A patent/NO339422B1/no not_active IP Right Cessation
- 2007-10-04 ZA ZA200708481A patent/ZA200708481B/xx unknown
- 2007-10-07 IL IL186409A patent/IL186409A/en active IP Right Grant
- 2007-10-08 MA MA30281A patent/MA29672B1/fr unknown
- 2007-10-08 TN TNP2007000380A patent/TNSN07380A1/fr unknown
- 2007-11-01 CR CR9493A patent/CR9493A/es not_active Application Discontinuation
-
2010
- 2010-08-30 US US12/870,928 patent/US8124639B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29672B1 (fr) | [3.1.0] hétéroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type I | |
| MA28094A1 (fr) | Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine | |
| TN2009000204A1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase | |
| EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
| TN2014000115A1 (fr) | Derives de pyrrolopyrimidines et de purines | |
| EP1673078A4 (fr) | Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer | |
| MA31183B1 (fr) | Inhibiteurs de mek | |
| TN2010000175A1 (fr) | Piperidino-dihydrothienopyrimidines substituees | |
| DE60224879D1 (de) | Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände | |
| MA27675A1 (fr) | Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques | |
| TNSN98045A1 (fr) | Derives de nicotinamide nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
| TN2009000138A1 (fr) | Biaryl-ether-urees | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| MA28270A1 (fr) | Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2 | |
| EP1490335A4 (fr) | Inhibiteurs de la dipeptidyl peptidase beta-amino heterocycliques pour le traitement ou la prevention du diabete | |
| ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
| MA27438A1 (fr) | Piperazines heterocycliques substituees pour le traitement de la schizophrenie | |
| ATE527261T1 (de) | 7-aryl-3,9-diazabicycloä3.3.1ünon-6-en-derivate und ihre verwendung als renin-inhibitoren zur behandlung von bluthochdruck, herz-kreislauf- erkrankungen und nierenkrankheiten | |
| MA35748B1 (fr) | Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines | |
| EP2091328A4 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
| EP1689713A4 (fr) | Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer | |
| MA37691B1 (fr) | 5-amino[1,4]thiazines comme inhibiteurs de bace1 | |
| DE60327811D1 (de) | Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen | |
| MA28562B1 (fr) | 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation |